ValiRx plc
VAL.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | -£0 | £0 | £0 |
| Revenue | – | £0 | £0 | £0 |
| % Growth | – | – | -100% | – |
| Gross Profit | – | -£0 | -£0 | -£0 |
| % Margin | – | -166.8% | – | -1,331.5% |
| EBITDA | – | -£0 | -£0 | -£0 |
| % Margin | – | -1,837.5% | – | -10,533.7% |
| Net Income | – | -£0 | -£0 | -£0 |
| % Margin | – | -1,898.1% | – | -10,440.4% |
| EPS Diluted | – | -0.007 | -0.007 | -0.01 |
| % Growth | – | 4.1% | 24.5% | – |
| Operating Cash Flow | – | -£0 | -£0 | -£0 |
| Capital Expenditures | – | -£0 | -£0 | -£0 |
| Free Cash Flow | – | -£0 | -£0 | -£0 |